<DOC>
	<DOC>NCT02767947</DOC>
	<brief_summary>A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study</brief_summary>
	<brief_title>Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis</brief_title>
	<detailed_description>A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects with Tinea Corporis</detailed_description>
	<mesh_term>Tinea</mesh_term>
	<criteria>Key Subjects (or legal guardian/caregiver) with the ability and willingness to sign a written informed consent and/or assent (age appropriate). Subject of either gender must be at least 2 years to &lt; 18 years of age (2 to 17 years, inclusive). Subjects with a clinical diagnosis of tinea corporis characterized by clinical evidence of a tinea infection (at least moderate erythema, mild scaling, and moderate pruritus) Subjects must be in good general health and free of any disease that in the Investigator's opinion might interfere with the study evaluations. Subjects/caregiver must be able to communicate, be able to understand the study procedures, and be willing to comply with the study requirements. Key Subjects with active atopic or contact dermatitis in the area to be treated. Subjects with severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection. Female subjects who are pregnant and/or nursing or planning a pregnancy during the course of the trial. Subjects who test positive for pregnancy after start of test treatment will be discontinued from test treatment but will be followed for safety purposes. Subjects who are immunocompromised (due to disease, e.g., HIV or medications). Subjects who have a recent history of or current drug or alcohol abuse.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>